Sponsors should use a two-question format to collect race and ethnicity data during clinical trials, US FDA explained in a newly updated guidance document.
The document, dated Oct. 26, is an update to 2005 policy. The agency considers it a "Level 2" guidance, meaning it addresses existing policy and does not need to be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?